Home / PDA Letter / Full Article

U.S. FDA Continues Data Integrity Focus

by Lina Genovesi

Published On Jul 9, 2019

A Review of U.S. Regulations on cGMP and Data Integrity

The U.S. FDA continues to inspect pharmaceutical facilities for compliance with cGMP regulations, and as a result of these inspections, has issued numerous warning letters citing several significant violations involving data integrity.

The contents of "U.S. FDA Continues Data Integrity Focus" are available to PDA members. Please sign up or log in to read the full article.